Dear Editor,

Influenza affects between two and three million people worldwide each year, with complications responsible for a significant number of excess hospitalizations in intensive care units (ICUs) \[[@CR1]\]. Since the newsworthy 2009 A(H1N1) pandemic (pdm), publications about influenza in ICUs remain scarce, with crucial outstanding issues on prognosis factors including the timing of antiviral treatments \[[@CR2]--[@CR5]\]. Here, we present a multicenter prospective study of critically ill influenza-infected patients aimed to identify prognosis factors associated with death.

This study was conducted from December 2008 to April 2013 in the 12 polyvalent ICUs from the Lyon catchment area (France). All adult patients admitted with microbiologically confirmed influenza infection were included. Following univariate comparisons, the independent contribution of patients' characteristics to in-hospital mortality was analyzed by backward stepwise multivariate analysis in a logistic regression model. Propensity score-matching was further used to compare similar patient populations receiving oseltamivir within or after 2 days of the onset of symptoms.

Over the study period, 201 patients were enrolled with the following main reasons for ICU admission: respiratory distress (*n* = 174, 87%), shock (*n* = 13, 6.5%), and neurological failure (*n* = 7, 3.5%). Infections were mostly caused by type A influenza virus (*n* = 171, 85%), with A(H1N1)pdm encountered in half of cases (*n* = 100, 50%). Other characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}. Only 40 (20%) patients received antiviral treatment by oseltamivir within 2 days of the onset of symptoms. Day-28, ICU, and in-hospital mortalities were 18% (37/201), 21% (43/201), and 26% (53/201), respectively. Survivors were more likely to have received early oseltamivir therapy, with a significant trend in proportions of in-hospital mortality with increasing time from onset of symptoms to initiation of treatment (*p* = 0.01). Oseltamivir administration within 2 days of the onset of symptoms appeared as the sole independent determinant of a favorable outcome (OR 0.26; 95% CI 0.08--0.79, *p* = 0.02). After propensity score-matched analysis, oseltamivir therapy within 2 days of the onset of symptoms was associated with reduced in-hospital mortality (Supplementary Table 1).Table 1Patients' characteristics according to outcomeTotal\
*n* = 201Survivors\
*n* = 148Non-survivors\
*n* = 53Univariate analysis *p*Multivariate analysis OR (95% CI)Clinical features Age^a^ (years)63 ± 1662 ± 1566 ± 170.0881.03 (1.00--1.05)\* Male sex107 (53)81 (55)26 (49)0.477 Influenza vaccination25 (12)19 (13)6 (11)0.773 BMI^a^ (kg m^−2^)27 ± 728 ± 726 ± 70.168 No comorbidity19 (9)14 (9)5 (9)0.996 SAPS II44 ± 1740 ± 1554 ± 17\< 0.001Clinical course Symptom duration before ICU admission (days)5.1 ± 5.05.1 ± 4.55.1 ± 6.00.931 Influenza diagnosis before ICU admission20 (10)14 (9.5)6 (11)0.698 Days from admission to influenza diagnosis^a^2.3 ± 3.42.0 ± 2.72.9 ± 4.90.112Microbiological results Viral subtype0.707  Influenza A(H1N1)pdm^a^100 (50)73 (49)27 (51)--  Other type A71 (35)54 (37)17 (32)--  Type B30 (15)21 (14)9 (17)-- Bacterial co-infection at admission48 (24)38 (26)10 (19)0.319 VAP in the evolution^a^51 (25)31 (21)20 (38)0.0161.91 (0.89--4.10)Initial organ failures Type  Respiratory109 (54)74 (50)35 (66)0.044  Cardiovascular86 (43)58 (39)28 (53)0.003  Neurological50 (25)30 (20)20 (38)0.011  Hematological24 (12)8 (5.4)16 (30)\< 0.001  Renal21 (10)10 (6.8)11 (21)0.004  Hepatic2 (1.0)1 (0.7)1 (1.9)0.459 Number of failed organs1.5 ± 1.21.2 ± 1.12.1 ± 1.2\< 0.001 SOFA score^a^6.6 ± 3.95.9 ± 3.88.7 ± 3.7\< 0.0011.19 (1.08--1.30)\*Organ support during ICU stay Mechanical ventilation179 (89)126 (85)53 (100)0.003  ARDS113 (56)73 (49)40 (75)0.001  NIV only36 (18)31 (22)5 (9.4)0.061  Days14 ± 2012 ± 1719 ± 280.084 ECMO^a^8 (4.0)4 (2.7)4 (7.5)0.211 Catecholamines (days)4.7 ± 8.83.3 ± 6.88.2 ± 12.40.005 RRT (days)3.9 ± 12.02.7 ± 8.87.3 ± 17.90.073Other treatments Prone position^a^38 (19)23 (15)15 (28)0.041 Neuromuscular blockade67 (33)45 (30)22 (42)0.141 Nitric oxide19 (9.5)11 (7.4)8 (15)0.101 Oseltamivir146 (73)109 (74)37 (70)0.591  Administration before ICU admission17 (8.5)13 (8.7)4 (7.5)0.999  Dose (mg/day)201 ± 84197 ± 82215 ± 980.257  ≤ 2 days after onset of symptoms^a^40 (20)36 (24)4 (7.5)0.0090.26 (0.08--0.79)\*  Days from onset of symptoms to initiation4.9 ± 3.54.6 ± 3.65.7 ± 3.10.086 Steroids^a^91 (45)63 (43)28 (53)0.288Data are number (%) or mean ± standard deviation, as appropriate*OR* odds ratio, *CI* confidence interval, *BMI* Body Mass Index, *ICU* intensive care units, *VAP* Ventilator-Associated Pneumonia, *ARDS* Acute Respiratory Distress Syndrome, *SOFA* Sepsis-Related Organ Failure Assessment, *NIV* non--invasive ventilation, *ECMO* extra-corporeal membrane oxygenation, *RRT* renal replacement therapy\**p* \< 0.05^a^Variables included in the backward stepwise logistic regression

The present study emphasizes the delay in oseltamivir administration as a major risk factor for in-hospital mortality. Influenza is a public health problem that, each year, causes both severe illness and deaths in high-risk populations \[[@CR1]\]. With the exception of the 2009 pandemic, data on critical illnesses attributable to influenza are scarce. Thus, we designed the present study to provide current information on influenza disease in ICUs in the real situation of a specific territory. Concerning the severity of the patients' illness or the risk factors of death, our cohort is in agreement with previous studies on influenza-associated critical illness mainly drawn from 2009 pandemic studies \[[@CR2], [@CR3]\]. Nevertheless, our study does not confirm the negative impact on patients' outcomes of the influenza A(H1N1)pdm virus subtype. Importantly, as confirmed by propensity analysis, oseltamivir administration was associated with better outcomes when administrated within 2 days of the onset of symptoms. This is the key message of our work, consistent with recent studies in non-severe forms of the disease, including meta-analysis of randomized clinical trials \[[@CR4]\]. Indeed, the recent literature highlights the efficacy of oseltamivir to reduce the duration of symptoms, respiratory tract complications, and hospital admittance \[[@CR4], [@CR5]\]. Our results extend to the ICU setting the relationship between the delay of oseltamivir administration and the effectiveness of the treatment in patients with either A(H1N1)pdm or other influenza virus subtypes.

In conclusion, this real-life study emphasizes oseltamivir efficacy on in-hospital outcome when administrated within 2 days of the onset of symptoms. Even if physicians' awareness of the influenza disease has been undeniably enhanced since the last pandemic, many efforts are still required to improve influenza-infected patient management in ICUs, including early oseltamivir administration.
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